{"gene":"CNR1","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1997,"finding":"CB1 receptor is a G protein-coupled receptor coupled to G proteins; it inhibits adenylyl cyclase and regulates ion channels in the CNS, and is activated by cannabinoid ligands including endogenous agonists.","method":"Pharmacological characterization, binding studies, effector system assays","journal":"Pharmacology & therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — extensively replicated across multiple labs using in vitro assays, binding studies, and functional effector measurements; foundational receptor pharmacology","pmids":["9336020"],"is_preprint":false},{"year":1998,"finding":"CB1 receptor couples to Gi/o proteins to inhibit adenylate cyclase, regulate Ca2+ channels and K+ channels, and stimulate the MAP kinase pathway; the juxtamembrane C-terminal region extending from helix VII is proposed to activate G proteins.","method":"Expression in cell lines, electrophysiology, biochemical effector assays","journal":"Neurobiology of disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs with functional effector assays and channel recordings","pmids":["9974174"],"is_preprint":false},{"year":1998,"finding":"Protein kinase C (PKC) phosphorylates a single serine (S317) in the third intracellular loop of CB1, and this phosphorylation disrupts CB1-mediated modulation of potassium and calcium channels; mutating S317 to alanine eliminated PKC-mediated disruption without affecting basal channel modulation.","method":"Site-directed mutagenesis, PKC phosphorylation of fusion protein, electrophysiology in AtT-20 cells transfected with rat CB1","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation assay plus mutagenesis plus functional electrophysiology, single lab but multiple orthogonal methods","pmids":["9526000"],"is_preprint":false},{"year":1999,"finding":"CB1 receptors are rapidly internalized following agonist binding via clathrin-coated pits; internalization does not require activated Gα subunits; a region of the extreme carboxy terminus (last 14 residues) is necessary for internalization. Recycling of sequestered receptor requires endosomal acidification and dephosphorylation.","method":"Pharmacological internalization assays with hypertonic sucrose blockade, C-terminal truncation mutants, new protein synthesis inhibition","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — domain-mapping with multiple truncation mutants, pharmacological dissection, and cell biological assays in a single lab","pmids":["10428044"],"is_preprint":false},{"year":1999,"finding":"GRK3 and β-arrestin 2 mediate homologous CB1 receptor desensitization; residues within the C-terminal tail (418–439), specifically phosphorylation sites S426 and S430, are required for GRK3/β-arrestin-dependent desensitization but not for internalization. CB1 desensitization and internalization are thus governed by distinct receptor domains.","method":"Xenopus oocyte expression system with GRK3/β-arrestin co-expression, K+ conductance electrophysiology, site-directed mutagenesis (S426A, S430A), AtT-20 cell internalization assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in oocyte system, mutagenesis, and multiple functional readouts in a single rigorous study","pmids":["10234009"],"is_preprint":false},{"year":2000,"finding":"CB1 receptor activation mediates cell migration (chemotaxis and chemokinesis) via pertussis toxin-sensitive Gi proteins; this migratory response depends on MAP kinase activation but not on adenylyl cyclase inhibition.","method":"Modified Boyden chamber migration assay in HEK293 cells stably expressing human CB1, pertussis toxin treatment, PD098059 (MEK inhibitor) treatment, SR141716A antagonism","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional migration assay with pharmacological dissection, single lab, two orthogonal mechanistic probes","pmids":["10871313"],"is_preprint":false},{"year":2004,"finding":"CB1 receptor signal transduction efficacy depends on coupling to Gi/o proteins, with evidence for regional differences in G protein selectivity in brain; CB1 can also interact with Gs or Gq in some cellular contexts.","method":"[35S]GTPγS binding assays, adenylyl cyclase assays, brain regional comparisons","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical assays across multiple brain regions, single review consolidating multiple experiments","pmids":["15308578"],"is_preprint":false},{"year":2009,"finding":"CB1R signals primarily through Gi/o proteins to inhibit adenylyl cyclase and regulate ion channels; it also activates MAPK pathways (p42/p44, p38, JNK) via Gi/o; activated/phosphorylated CB1R associates with β-arrestins, forming signaling complexes; CB1R can form homo- and heterodimers/oligomers with altered pharmacological properties.","method":"Biochemical assays, co-immunoprecipitation, resonance energy transfer approaches, functional signaling assays","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling assays cited from multiple studies, review consolidating replicated findings","pmids":["19620237"],"is_preprint":false},{"year":2010,"finding":"CB1 receptor physically interacts with β2-adrenoceptors as demonstrated by BRET; co-expression of β2-adrenoceptors reduces CB1 constitutive activity, increases CB1 cell-surface expression, enhances Gαi-dependent ERK phosphorylation, and decreases non-Gαi-mediated CREB phosphorylation. These interactions were confirmed in primary human trabecular meshwork cells endogenously co-expressing both receptors.","method":"Bioluminescence resonance energy transfer (BRET), co-expression in HEK293H cells, ERK and CREB signaling assays, primary human ocular cell experiments","journal":"British journal of pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — BRET physical interaction plus functional signaling assays in both heterologous and endogenous cell system","pmids":["20590567"],"is_preprint":false},{"year":2012,"finding":"CB1 and CB2 receptors form functional heteromers in transfected neuronal cells and in rat brain (pineal gland, nucleus accumbens, globus pallidus); within CB1-CB2 heteromers, co-activation produces negative cross-talk in Akt phosphorylation and neurite outgrowth; CB1 antagonists can block CB2 agonist effects and vice versa (bidirectional cross-antagonism).","method":"Biophysical (BRET/FRET) and biochemical (co-immunoprecipitation) approaches in transfected neuronal cells and rat brain tissue; Akt phosphorylation and neurite outgrowth assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP plus biophysical BRET/FRET plus functional cross-antagonism assays, demonstrated in both transfected cells and native brain tissue","pmids":["22532560"],"is_preprint":false},{"year":2012,"finding":"CB1 receptor co-expression with GPR55 leads to heteromer formation; this heteromer inhibits GPR55-mediated NFAT and SRE transcription factor activation and ERK1/2 activation; conversely, GPR55 presence enhances CB1R-mediated ERK1/2 and NFAT activation. Internalization of both receptors is not affected by heteromerization.","method":"Co-immunoprecipitation, BRET, transcription factor reporter assays (NFAT, SRE), ERK1/2 phosphorylation assays in HEK293 cells","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — BRET plus co-IP plus functional signaling assays, single lab","pmids":["23161546"],"is_preprint":false},{"year":2013,"finding":"CB1 receptor activation by AEA or ACEA (CB1-specific agonist) enhances neuronal differentiation of neural stem cells but not astrocyte or oligodendrocyte differentiation; CB1 activation causes long-term inhibition of ERK1/2 signaling, and pharmacological inhibition of ERK1/2 recapitulates the pro-neuronal differentiation effect.","method":"Pharmacological activation/antagonism in mouse NSCs, RT-PCR, Western blot, morphometric analysis, gene array profiling, ERK1/2 pathway inhibition","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CB1-specific agonist/antagonist combined with pathway inhibition and multiple readouts, single lab","pmids":["23372698"],"is_preprint":false},{"year":2008,"finding":"Loss of CB1 function (pharmacological or genetic, Cnr1 knockout) in mice causes defects in axonal growth and fasciculation during embryonic development; CB1 is required for normal axonal pathfinding in vivo.","method":"CB1 pharmacological inhibition, morpholino knockdown in zebrafish, loss-of-function phenotype analysis (axon pathfinding/fasciculation)","journal":"Molecular and cellular neurosciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological plus genetic (morpholino) knockdown with defined developmental phenotype in two model systems","pmids":["18378465"],"is_preprint":false},{"year":2008,"finding":"Genetic inactivation of CB1 (Cnr1 knockout), but not CB2, induces preterm birth in mice; CB1 deficiency alters progesterone/estrogen ratios before parturition; CB1 inactivation causes aberrant CRH and corticosterone secretion, and a CRH antagonist restores normal parturition timing in Cnr1 null mice.","method":"Cnr1 and Cnr2 targeted deletion mouse models, pharmacological inactivation, radioimmunoassay for steroid hormones, CRH antagonist rescue","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO plus pharmacological rescue with endocrine measurements, multiple orthogonal approaches in a single rigorous study","pmids":["18833324"],"is_preprint":false},{"year":2006,"finding":"CB1 receptor mediates cannabinoid-induced suppression of glutamatergic (Schaffer collateral-CA1) synaptic transmission in the hippocampus; CB1 knockout mice of two independent lines show no cannabinoid-mediated suppression at this synapse.","method":"Extracellular field recordings in hippocampal slices from two independently generated CB1-/- mouse lines vs. wild-type controls","journal":"Neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across two independent CB1 KO mouse lines with electrophysiological recordings","pmids":["16527424"],"is_preprint":false},{"year":2011,"finding":"CB1 receptor signaling promotes angiogenesis; siRNA-mediated knockdown or pharmacological antagonism of CB1 inhibits bFGF-induced endothelial proliferation, migration, and capillary-like tube formation via ERK, Akt, FAK, JNK, Rho, and MMP-2 pathways; CB1 blockade also inhibits neovascular growth in vivo (rabbit cornea assay and mouse retinopathy model).","method":"siRNA knockdown, pharmacological antagonism, in vitro endothelial proliferation/migration/tube formation assays, in vivo corneal and retinal neovascularization models","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological loss-of-function with multiple in vitro and in vivo readouts, multiple signaling pathway measurements","pmids":["21460248"],"is_preprint":false},{"year":2019,"finding":"Crystal structure of CB1 bound to the negative allosteric modulator (NAM) ORG27569 and agonist CP55940 reveals that ORG27569 binds to an extrahelical site within the inner leaflet of the membrane overlapping with a conserved cholesterol interaction site; the ternary complex captures an intermediate receptor state where aromatic residues at the base of the agonist-binding pocket adopt inactive conformation despite orthosteric pocket contraction.","method":"X-ray crystallography of CB1 ternary complex (NAM + agonist)","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure with functional context, single lab but definitive structural method","pmids":["31659318"],"is_preprint":false},{"year":2022,"finding":"The positive allosteric modulator (PAM) ZCZ011 binds to an extrahelical site at the TM2-TM3-TM4 surface of CB1; TM2 rearrangement is critical for allosteric signal propagation; ZCZ011 promotes TM2 rearrangement favoring receptor activation, while the NAM ORG27569 (also binding TM2-TM3-TM4) impedes TM2 rearrangement. Both allosteric modulators converge on the same TM2 rearrangement mechanism.","method":"X-ray crystallography, cryo-EM structures of CB1 with PAM ZCZ011, unbiased and biased molecular dynamics simulations, site-directed mutagenesis, functional signaling assays","journal":"Nature chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure and cryo-EM combined with MD simulations and mutagenesis in a single rigorous multi-method study","pmids":["35637350"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structure of CB1 bound to an endocannabinoid analog (AMG315) in an active signaling complex reveals ligand binding pocket details; ligand interactions with TM2 residues drive conformational changes on the intracellular side of TM2 that are unique to CB1 and are a determinant of G protein activation efficacy; the 'toggle switch' residues F200(3.36) and W356(6.48) are functionally important for activation.","method":"Cryo-EM structure determination of agonist-CB1-G protein complex, molecular docking, molecular dynamics simulations, mutagenesis, signaling assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure combined with MD simulations, mutagenesis, and functional signaling assays in a single rigorous study","pmids":["37160876"],"is_preprint":false},{"year":2025,"finding":"A cryptic pocket in CB1 (identified by molecular dynamics simulations, leading to D2.50) can be targeted by positively charged agonist derivatives to achieve peripheral restriction and dampened arrestin recruitment; the lead ligand VIP36 occupying this cryptic pocket shows 100-fold dose separation between peripheral analgesic efficacy and centrally mediated side effects in mouse pain models, with limited tolerance development.","method":"Computational MD simulation-guided design, structure determination, pharmacological assays for G protein vs arrestin signaling bias, in vivo mouse pain models (three models), PK studies","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure determination plus mutagenesis/pharmacology plus in vivo validation with multiple orthogonal methods in a single rigorous study","pmids":["40044849"],"is_preprint":false},{"year":2018,"finding":"CB1 receptors specifically in hippocampal GABAergic neurons are necessary and sufficient for mediated (incidental) learning; deletion and re-expression of CB1R in hippocampal GABAergic neurons abolishes and rescues mediated learning respectively; paired sensory cues induce protein synthesis-dependent upregulation of hippocampal CB1R expression and facilitate long-term plasticity at inhibitory synapses.","method":"Cell-type-specific CB1R deletion and re-expression (conditional KO and rescue), sensory preconditioning behavioral paradigm, chemogenetic manipulation of hippocampal GABAergic neurons, electrophysiology for synaptic plasticity","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with cell-type-specific rescue plus chemogenetics plus synaptic plasticity recordings, multiple orthogonal approaches","pmids":["30174119"],"is_preprint":false},{"year":2016,"finding":"CB1 receptors in hippocampal GABAergic interneurons inhibit GABA release; deletion of CB1R from GABAergic neurons enhances frequency and kinetics of spontaneous IPSCs in CA1 pyramidal neurons and impairs acquisition of spatial memory and novel object recognition, without affecting tonic inhibition, paired-pulse facilitation, or LTP.","method":"Cell-type-specific CB1R knockout in GABAergic neurons, patch clamp and field potential recordings, behavioral cognitive testing","journal":"Pflugers Archiv","confidence":"High","confidence_rationale":"Tier 2 / Moderate — conditional KO with electrophysiology and behavioral phenotyping, multiple orthogonal readouts","pmids":["26739712"],"is_preprint":false},{"year":2004,"finding":"Expression of CB1 mRNA in the striatum of Huntington's disease transgenic mice (R6/1, R6/2) is progressively reduced due to decreased transcription; the CB1 gene has two exons separated by an 18.4 kb intron with a GC-rich promoter; the progressive decline is caused by altered transcription factor activity due to mutant huntingtin expression.","method":"RT-PCR, promoter analysis, transcription start site mapping, comparison of HD transgenic vs wild-type mice at multiple ages","journal":"European journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene structure characterization plus functional transcription analysis in transgenic disease model, single lab","pmids":["15606779"],"is_preprint":false},{"year":2019,"finding":"CB1 receptor forms heteromers with Smoothened (Smo), the Hedgehog pathway transducer, as demonstrated by proximity ligation assay; cannabinoids reduce Shh signaling by inhibiting Smo, and a CB1 receptor antagonist attenuates cannabinoid-induced birth defects; CB1-Smo heteromers suggest allosteric CB1-Smo interaction.","method":"Proximity ligation assay (PLA) in mouse/zebrafish embryo models, CB1 antagonist rescue, Shh pathway reporter assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — proximity ligation (single method for interaction) plus pharmacological rescue, single lab","pmids":["31690747"],"is_preprint":false},{"year":2020,"finding":"CB1 receptor activation (ACEA) protects against brain ischemia/reperfusion injury by inhibiting mitochondrial fission via Drp1; CB1 agonist ACEA reduced OGD/R-induced neuronal injury and MCAO-induced infarct volume; neuroprotective effects were blocked by CB1 antagonist AM251 or Drp1 upregulation, establishing a CB1-Drp1 pathway.","method":"OGD/R model in neuronal cells, MCAO rat model, co-administration of CB1 antagonist AM251 and Drp1 overexpression, mitochondrial fission and apoptosis assays","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological intervention with genetic Drp1 manipulation in both in vitro and in vivo models, single lab","pmids":["33083022"],"is_preprint":false},{"year":2022,"finding":"CB1 receptor activation in human bone marrow MSCs enhances osteogenic differentiation and rescues mitochondrial energy metabolism (OCR and mitochondrial membrane potential) impaired by inflammatory cytokines; CB1 activation promotes JNK and p38 MAPK signaling and inhibits ERK1/2; this effect was linked to enhanced mitochondrial electron transport chain activity.","method":"CB1 agonist/antagonist treatment, CB1 knockdown, Seahorse metabolic analysis, JC-10 MMP assay, Western blot for MAPK pathways, osteogenic differentiation assays","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CB1 knockdown plus pharmacological activation with functional metabolic and differentiation readouts, single lab","pmids":["35063024"],"is_preprint":false},{"year":2008,"finding":"CB1 receptor is expressed specifically in pancreatic delta-cells (somatostatin-positive) in mouse, rat, and human islets; CB1 is not detected in alpha-, beta-, or PP-cells of islets; monoacylglycerol lipase (MAGL) is expressed in delta-cells and FAAH in alpha-cells.","method":"Confocal immunofluorescence microscopy with co-localization for somatostatin, insulin, glucagon markers; RT-PCR in islets and cell lines","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — immunofluorescence co-localization in three species (mouse, rat, human) with cell-type markers, single lab","pmids":["18505678"],"is_preprint":false},{"year":2017,"finding":"CB1 receptors are functionally present within brain mitochondria (mtCB1); acute activation of mtCB1 alters mitochondrial ATP generation, synaptic transmission, and memory performance.","method":"Mitochondrial fractionation, functional assays of mitochondrial ATP production, synaptic transmission measurements, memory behavioral tests","journal":"BioEssays","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review consolidating subcellular fractionation and functional data from multiple studies","pmids":["29058339"],"is_preprint":false},{"year":2008,"finding":"CB1 receptor activation inhibits trigeminovascular neuronal responses to A- and C-fiber inputs from the dura mater; this inhibition is blocked by CB1 antagonist SR141716 but not CB2 antagonist AM630, establishing CB1-mediated inhibition of trigeminocervical complex neurons.","method":"Extracellular electrophysiology of TCC neurons in rats, cannabinoid agonist WIN55,212 and anandamide treatment with selective antagonists SR141716 and AM630","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo electrophysiology with selective antagonist dissection, single lab","pmids":["17018694"],"is_preprint":false},{"year":2008,"finding":"CB1 receptor mRNA expression in the Fallopian tube shows temporal (luteal > follicular) variation likely regulated by progesterone; CB1 mRNA is attenuated in Fallopian tube and decidua of women with ectopic pregnancy, suggesting that CB1 signaling regulates embryo transport in the human oviduct.","method":"RT-PCR and immunohistochemistry of timed Fallopian tube biopsies from women with and without ectopic pregnancy","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — expression analysis (RT-PCR/IHC) with clinical correlation, no direct functional manipulation","pmids":["19093002"],"is_preprint":false}],"current_model":"CNR1 encodes CB1, a class A GPCR that couples primarily to Gi/o proteins to inhibit adenylyl cyclase, suppress voltage-gated Ca2+ channels, activate inwardly rectifying K+ channels, and stimulate MAPK pathways; it undergoes GRK3/β-arrestin-2-mediated homologous desensitization via phosphorylation of S426/S430 on its C-terminal tail, and agonist-driven internalization via clathrin-coated pits dependent on the distal C-terminus; structurally, it possesses an orthosteric ligand-binding pocket and an extrahelical allosteric site at TM2-TM3-TM4 where both positive and negative allosteric modulators act by promoting or impeding TM2 rearrangement; a cryptic pocket near D2.50 can be targeted to achieve peripheral restriction and biased (G protein-favored) signaling; CB1 forms functional heteromers with CB2, GPR55, β2-adrenoceptors, and Smoothened with distinct signaling consequences; it is expressed presynaptically in neurons to mediate retrograde inhibition of neurotransmitter release, in hippocampal GABAergic interneurons to control inhibitory transmission and specific forms of learning, within mitochondria to regulate ATP production, and in peripheral tissues including intestinal epithelium, endothelial cells, and pancreatic delta-cells to modulate permeability, angiogenesis, and islet hormone secretion, respectively."},"narrative":{"mechanistic_narrative":"CNR1 encodes CB1, a class A G protein-coupled receptor that couples predominantly to Gi/o proteins to inhibit adenylyl cyclase, regulate Ca2+ and K+ channels, and stimulate MAPK cascades (p42/p44, p38, JNK), with regional and context-dependent flexibility in G protein selectivity [PMID:9336020, PMID:9974174, PMID:15308578, PMID:19620237]. Signaling output is shaped by phosphorylation-dependent regulation: PKC phosphorylates S317 in the third intracellular loop to disrupt channel modulation [PMID:9526000], while GRK3/β-arrestin-2 acting on C-terminal sites S426/S430 drive homologous desensitization, a process governed by a receptor domain distinct from the extreme C-terminal region required for clathrin-mediated agonist-induced internalization [PMID:10428044, PMID:10234009, PMID:19620237]. Structural studies define an orthosteric agonist pocket with F200(3.36)/W356(6.48) toggle-switch residues and TM2-dependent intracellular conformational changes that determine G protein activation efficacy, plus an extrahelical TM2-TM3-TM4 allosteric site where positive and negative modulators converge on TM2 rearrangement, and a cryptic pocket near D2.50 exploitable for peripherally restricted, G protein-biased analgesia [PMID:31659318, PMID:35637350, PMID:37160876, PMID:40044849]. CB1 forms functional heteromers with β2-adrenoceptors, CB2, GPR55, and Smoothened, each reconfiguring downstream signaling and cross-regulation [PMID:20590567, PMID:22532560, PMID:23161546, PMID:31690747]. Functionally, CB1 in hippocampal GABAergic interneurons inhibits GABA release to control inhibitory transmission, spatial memory, and mediated learning [PMID:30174119, PMID:26739712], mediates retrograde suppression of glutamatergic transmission [PMID:16527424], and acts during development in axonal pathfinding and parturition timing [PMID:18378465, PMID:18833324]. It also operates in non-neuronal contexts including endothelial angiogenesis [PMID:21460248], mitochondrial ATP regulation and Drp1-dependent fission [PMID:33083022, PMID:29058339], and is expressed selectively in pancreatic delta-cells [PMID:18505678]. Reduced CB1 transcription in striatum accompanies Huntington's disease progression in transgenic mice [PMID:15606779].","teleology":[{"year":1998,"claim":"Established CB1 as a Gi/o-coupled GPCR whose juxtamembrane C-terminal region engages G proteins to inhibit adenylyl cyclase, regulate ion channels, and activate MAPK, defining the core transduction logic of the receptor.","evidence":"Pharmacological characterization, cell line expression, electrophysiology, and biochemical effector assays","pmids":["9336020","9974174"],"confidence":"High","gaps":["Did not resolve atomic basis of G protein selectivity","Context-dependent Gs/Gq coupling not yet defined"]},{"year":1999,"claim":"Resolved that desensitization and internalization of CB1 are governed by distinct receptor domains — GRK3/β-arrestin-2 acting on C-terminal S426/S430 versus a separate distal C-terminal sequence for clathrin-mediated endocytosis — plus PKC-dependent S317 modulation, clarifying how receptor signaling is independently regulated.","evidence":"Site-directed mutagenesis, in vitro phosphorylation, oocyte and AtT-20 reconstitution, internalization assays, electrophysiology","pmids":["9526000","10428044","10234009"],"confidence":"High","gaps":["Did not identify phosphatases driving recycling-coupled dephosphorylation","In vivo physiological consequences of each phosphosite not addressed"]},{"year":2000,"claim":"Showed CB1 drives cell migration through Gi-dependent MAPK activation independent of adenylyl cyclase inhibition, demonstrating effector-branch-specific physiological outputs.","evidence":"Boyden chamber migration assays in CB1-expressing HEK293 cells with pertussis toxin and MEK inhibitor dissection","pmids":["10871313"],"confidence":"Medium","gaps":["Heterologous overexpression system only","Endogenous migratory contexts not tested"]},{"year":2006,"claim":"Genetically established CB1 as the obligatory mediator of cannabinoid-induced suppression of glutamatergic transmission in hippocampus, confirming its role in synaptic signaling in native tissue.","evidence":"Field recordings in hippocampal slices from two independent CB1 knockout lines","pmids":["16527424"],"confidence":"High","gaps":["Did not localize the presynaptic source of receptor","Retrograde messenger identity not addressed here"]},{"year":2008,"claim":"Defined developmental, endocrine, and tissue-specific roles of CB1 — axonal pathfinding, parturition timing via CRH/steroid regulation, delta-cell-restricted islet expression, and trigeminovascular inhibition — broadening the receptor beyond classical neuromodulation.","evidence":"Cnr1 knockout/morpholino phenotyping, CRH antagonist rescue with steroid radioimmunoassay, islet immunofluorescence across three species, in vivo TCC electrophysiology","pmids":["18378465","18833324","18505678","17018694"],"confidence":"High","gaps":["Delta-cell CB1 signaling output on hormone secretion not functionally tested","Cell-autonomous versus systemic contributions to parturition unresolved"]},{"year":2012,"claim":"Demonstrated that CB1 physically heteromerizes with β2-adrenoceptors, CB2, and GPR55, reconfiguring constitutive activity, surface expression, and ERK/Akt/NFAT signaling, establishing receptor-receptor crosstalk as a layer of CB1 regulation.","evidence":"BRET/FRET, reciprocal co-immunoprecipitation, transcription reporter and phosphorylation assays in heterologous cells, native brain tissue, and primary ocular cells","pmids":["20590567","22532560","23161546"],"confidence":"High","gaps":["Stoichiometry and structural interface of heteromers undefined","Physiological prevalence of each heteromer in vivo not quantified"]},{"year":2018,"claim":"Showed CB1 in hippocampal GABAergic neurons is necessary and sufficient for inhibitory transmission control and specific forms of learning, pinpointing a defined neural circuit substrate for CB1 cognitive function.","evidence":"Cell-type-specific conditional knockout and rescue, chemogenetics, sensory preconditioning behavior, IPSC and plasticity recordings","pmids":["30174119","26739712"],"confidence":"High","gaps":["Molecular mechanism of activity-dependent CB1 upregulation not defined","Generalizability beyond hippocampal GABAergic neurons untested"]},{"year":2019,"claim":"Crystallography revealed an extrahelical allosteric site overlapping a cholesterol interaction site and captured an intermediate receptor state, providing the structural basis for allosteric modulation of CB1.","evidence":"X-ray crystallography of CB1 ternary complex with NAM ORG27569 and agonist CP55940","pmids":["31659318"],"confidence":"High","gaps":["Single allosteric modulator captured","Did not yet define the mechanistic step linking allosteric site to activation"]},{"year":2022,"claim":"Established that positive and negative allosteric modulators binding the TM2-TM3-TM4 surface converge on a shared TM2 rearrangement that gates activation, unifying the mechanism of bidirectional allosteric control.","evidence":"Crystallography, cryo-EM with PAM ZCZ011, biased/unbiased MD simulations, mutagenesis, signaling assays","pmids":["35637350"],"confidence":"High","gaps":["Kinetics of TM2 transition not quantified","Endogenous regulators of this site unknown"]},{"year":2023,"claim":"Active-state cryo-EM defined ligand-driven TM2 conformational changes unique to CB1 and toggle-switch residues F200/W356 as determinants of G protein activation efficacy, linking ligand chemistry to coupling output.","evidence":"Cryo-EM of agonist-CB1-G protein complex, docking, MD, mutagenesis, signaling assays","pmids":["37160876"],"confidence":"High","gaps":["Arrestin-bound active state not resolved here","Determinants of biased signaling not yet structurally mapped"]},{"year":2025,"claim":"Identified a cryptic D2.50 pocket targetable to achieve peripherally restricted, G protein-biased agonism with separation of analgesia from central side effects, demonstrating actionable structure-guided pharmacology.","evidence":"MD-guided design, structure determination, biased signaling pharmacology, three in vivo mouse pain models, PK studies","pmids":["40044849"],"confidence":"High","gaps":["Long-term safety and clinical translation untested","Endogenous role of this cryptic pocket unknown"]},{"year":null,"claim":"How CB1 subcellular pools — plasma membrane, mitochondria, and heteromeric assemblies — are coordinated to produce distinct physiological outputs in a given cell remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Mechanism targeting CB1 to mitochondria undefined","Quantitative partitioning between signaling pools unknown","Integration of heteromer-specific signaling in native tissue not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,6,7]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[8,9,10]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,8]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[24,27]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,7]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[14,20,21]}],"complexes":[],"partners":["CB2","GPR55","ADRB2","SMO","ARRB2","GRK3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P21554","full_name":"Cannabinoid receptor 1","aliases":["CANN6"],"length_aa":472,"mass_kda":52.9,"function":"G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727, PubMed:35637350). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca(2+) channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a pro-inflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells (PubMed:23955712) Binds both 2-arachidonoylglycerol (2-AG) and anandamide Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 2 in assays measuring GTP binding to membranes Only binds 2-arachidonoylglycerol (2-AG) with high affinity. Contrary to its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform 3 in assays measuring GTP binding to membranes","subcellular_location":"Cell membrane; Membrane raft; Mitochondrion outer membrane; Cell projection, axon; Presynapse","url":"https://www.uniprot.org/uniprotkb/P21554/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CNR1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CNR1","total_profiled":1310},"omim":[{"mim_id":"618538","title":"CANNABINOID RECEPTOR-INTERACTING PROTEIN 1; CNRIP1","url":"https://www.omim.org/entry/618538"},{"mim_id":"615687","title":"BECLIN 2; BECN2","url":"https://www.omim.org/entry/615687"},{"mim_id":"615353","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 28A; CCDC28A","url":"https://www.omim.org/entry/615353"},{"mim_id":"613599","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 12, LYSOPHOSPHOLIPASE; ABHD12","url":"https://www.omim.org/entry/613599"},{"mim_id":"609699","title":"MONOGLYCERIDE LIPASE; MGLL","url":"https://www.omim.org/entry/609699"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Actin filaments","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":18.3},{"tissue":"brain","ntpm":18.6}],"url":"https://www.proteinatlas.org/search/CNR1"},"hgnc":{"alias_symbol":["CB1K5","CB-R","CB1","CANN6","CB1A"],"prev_symbol":["CNR"]},"alphafold":{"accession":"P21554","domains":[{"cath_id":"1.20.1070.10","chopping":"105-312_334-411","consensus_level":"medium","plddt":91.2647,"start":105,"end":411}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P21554","model_url":"https://alphafold.ebi.ac.uk/files/AF-P21554-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P21554-F1-predicted_aligned_error_v6.png","plddt_mean":71.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CNR1","jax_strain_url":"https://www.jax.org/strain/search?query=CNR1"},"sequence":{"accession":"P21554","fasta_url":"https://rest.uniprot.org/uniprotkb/P21554.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P21554/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P21554"}},"corpus_meta":[{"pmid":"9336020","id":"PMC_9336020","title":"Pharmacology of cannabinoid CB1 and CB2 receptors.","date":"1997","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/9336020","citation_count":1199,"is_preprint":false},{"pmid":"15670612","id":"PMC_15670612","title":"Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15670612","citation_count":358,"is_preprint":false},{"pmid":"18584858","id":"PMC_18584858","title":"Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review.","date":"2008","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/18584858","citation_count":332,"is_preprint":false},{"pmid":"28826534","id":"PMC_28826534","title":"CB1 and CB2 Receptor Pharmacology.","date":"2017","source":"Advances in pharmacology (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28826534","citation_count":262,"is_preprint":false},{"pmid":"19620237","id":"PMC_19620237","title":"Signal transduction of the CB1 cannabinoid receptor.","date":"2009","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/19620237","citation_count":259,"is_preprint":false},{"pmid":"10428044","id":"PMC_10428044","title":"Internalization and recycling of the CB1 cannabinoid receptor.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10428044","citation_count":244,"is_preprint":false},{"pmid":"20166926","id":"PMC_20166926","title":"CB(1) cannabinoid receptors and their associated proteins.","date":"2010","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20166926","citation_count":225,"is_preprint":false},{"pmid":"10234009","id":"PMC_10234009","title":"Distinct domains of the CB1 cannabinoid receptor mediate desensitization and internalization.","date":"1999","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/10234009","citation_count":209,"is_preprint":false},{"pmid":"22532560","id":"PMC_22532560","title":"Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22532560","citation_count":192,"is_preprint":false},{"pmid":"12082570","id":"PMC_12082570","title":"CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.","date":"2002","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/12082570","citation_count":166,"is_preprint":false},{"pmid":"31659318","id":"PMC_31659318","title":"Structure of an allosteric modulator bound to the CB1 cannabinoid receptor.","date":"2019","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/31659318","citation_count":150,"is_preprint":false},{"pmid":"9106242","id":"PMC_9106242","title":"Cannabinoid receptor gene (CNR1): association with i.v. drug use.","date":"1997","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9106242","citation_count":138,"is_preprint":false},{"pmid":"12550742","id":"PMC_12550742","title":"CB1 cannabinoid receptor signalling in Parkinson's disease.","date":"2003","source":"Current opinion in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12550742","citation_count":131,"is_preprint":false},{"pmid":"9526000","id":"PMC_9526000","title":"Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor.","date":"1998","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9526000","citation_count":127,"is_preprint":false},{"pmid":"18378465","id":"PMC_18378465","title":"The endocannabinoid receptor, CB1, is required for normal axonal growth and fasciculation.","date":"2008","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18378465","citation_count":119,"is_preprint":false},{"pmid":"16527424","id":"PMC_16527424","title":"The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus.","date":"2006","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16527424","citation_count":111,"is_preprint":false},{"pmid":"20080186","id":"PMC_20080186","title":"Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression.","date":"2010","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/20080186","citation_count":106,"is_preprint":false},{"pmid":"24882055","id":"PMC_24882055","title":"Stress regulates endocannabinoid-CB1 receptor signaling.","date":"2014","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24882055","citation_count":103,"is_preprint":false},{"pmid":"20010552","id":"PMC_20010552","title":"Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues.","date":"2009","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20010552","citation_count":99,"is_preprint":false},{"pmid":"22669173","id":"PMC_22669173","title":"Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22669173","citation_count":98,"is_preprint":false},{"pmid":"15935455","id":"PMC_15935455","title":"CB1 receptor antagonists for the treatment of nicotine addiction.","date":"2005","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/15935455","citation_count":94,"is_preprint":false},{"pmid":"18406468","id":"PMC_18406468","title":"Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!","date":"2008","source":"Journal of neuroscience methods","url":"https://pubmed.ncbi.nlm.nih.gov/18406468","citation_count":94,"is_preprint":false},{"pmid":"31690747","id":"PMC_31690747","title":"Cannabinoids Exacerbate Alcohol Teratogenesis by a CB1-Hedgehog Interaction.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31690747","citation_count":89,"is_preprint":false},{"pmid":"16570100","id":"PMC_16570100","title":"Mechanisms of CB1 receptor signaling: endocannabinoid modulation of synaptic strength.","date":"2006","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/16570100","citation_count":88,"is_preprint":false},{"pmid":"16623851","id":"PMC_16623851","title":"Variations in the human cannabinoid receptor (CNR1) gene modulate striatal responses to happy faces.","date":"2006","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16623851","citation_count":87,"is_preprint":false},{"pmid":"17018694","id":"PMC_17018694","title":"Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons.","date":"2006","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17018694","citation_count":87,"is_preprint":false},{"pmid":"15606779","id":"PMC_15606779","title":"Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.","date":"2004","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15606779","citation_count":87,"is_preprint":false},{"pmid":"15668727","id":"PMC_15668727","title":"Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1).","date":"2005","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/15668727","citation_count":86,"is_preprint":false},{"pmid":"34500853","id":"PMC_34500853","title":"CB1 Cannabinoid Receptor Signaling and Biased Signaling.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34500853","citation_count":85,"is_preprint":false},{"pmid":"15755787","id":"PMC_15755787","title":"Rimonabant--a selective CB1 antagonist.","date":"2005","source":"The Annals of pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/15755787","citation_count":85,"is_preprint":false},{"pmid":"18279497","id":"PMC_18279497","title":"Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.","date":"2008","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/18279497","citation_count":85,"is_preprint":false},{"pmid":"18213623","id":"PMC_18213623","title":"Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18213623","citation_count":83,"is_preprint":false},{"pmid":"23902803","id":"PMC_23902803","title":"Peripherally restricted CB1 receptor blockers.","date":"2013","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/23902803","citation_count":82,"is_preprint":false},{"pmid":"27879006","id":"PMC_27879006","title":"Allosteric Modulation: An Alternate Approach Targeting the Cannabinoid CB1 Receptor.","date":"2016","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/27879006","citation_count":81,"is_preprint":false},{"pmid":"35637350","id":"PMC_35637350","title":"Molecular mechanism of allosteric modulation for the cannabinoid receptor CB1.","date":"2022","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/35637350","citation_count":81,"is_preprint":false},{"pmid":"23161546","id":"PMC_23161546","title":"The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23161546","citation_count":81,"is_preprint":false},{"pmid":"18482432","id":"PMC_18482432","title":"The role of CB1 receptors in psychostimulant addiction.","date":"2008","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/18482432","citation_count":81,"is_preprint":false},{"pmid":"23108542","id":"PMC_23108542","title":"Endocannabinoids via CB₁ receptors act as neurogenic niche cues during cortical development.","date":"2012","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23108542","citation_count":78,"is_preprint":false},{"pmid":"23261520","id":"PMC_23261520","title":"The role of CB1 in immune modulation by cannabinoids.","date":"2012","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23261520","citation_count":74,"is_preprint":false},{"pmid":"23372698","id":"PMC_23372698","title":"Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23372698","citation_count":74,"is_preprint":false},{"pmid":"21460248","id":"PMC_21460248","title":"Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis.","date":"2011","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/21460248","citation_count":73,"is_preprint":false},{"pmid":"23647582","id":"PMC_23647582","title":"CB1 receptor signaling regulates social anxiety and memory.","date":"2013","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/23647582","citation_count":72,"is_preprint":false},{"pmid":"20590567","id":"PMC_20590567","title":"Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.","date":"2010","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20590567","citation_count":72,"is_preprint":false},{"pmid":"25967266","id":"PMC_25967266","title":"Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25967266","citation_count":71,"is_preprint":false},{"pmid":"18824122","id":"PMC_18824122","title":"CB(1) receptor antagonism: biological basis for metabolic effects.","date":"2008","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/18824122","citation_count":71,"is_preprint":false},{"pmid":"18186055","id":"PMC_18186055","title":"Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18186055","citation_count":68,"is_preprint":false},{"pmid":"10441206","id":"PMC_10441206","title":"A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene.","date":"1999","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/10441206","citation_count":67,"is_preprint":false},{"pmid":"32433545","id":"PMC_32433545","title":"Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia.","date":"2020","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32433545","citation_count":66,"is_preprint":false},{"pmid":"28334603","id":"PMC_28334603","title":"The CB1 Receptor as the Cornerstone of Exostasis.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28334603","citation_count":65,"is_preprint":false},{"pmid":"31013934","id":"PMC_31013934","title":"Structural Insights into CB1 Receptor Biased Signaling.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31013934","citation_count":65,"is_preprint":false},{"pmid":"19093002","id":"PMC_19093002","title":"CB1 expression is attenuated in Fallopian tube and decidua of women with ectopic pregnancy.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19093002","citation_count":63,"is_preprint":false},{"pmid":"19725030","id":"PMC_19725030","title":"Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype.","date":"2009","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19725030","citation_count":62,"is_preprint":false},{"pmid":"28527758","id":"PMC_28527758","title":"Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.","date":"2017","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28527758","citation_count":61,"is_preprint":false},{"pmid":"11204352","id":"PMC_11204352","title":"Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia.","date":"2000","source":"Psychiatric genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11204352","citation_count":61,"is_preprint":false},{"pmid":"24836296","id":"PMC_24836296","title":"Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.","date":"2014","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/24836296","citation_count":60,"is_preprint":false},{"pmid":"16026309","id":"PMC_16026309","title":"CB1 cannabinoid receptor ligands.","date":"2005","source":"Mini reviews in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16026309","citation_count":59,"is_preprint":false},{"pmid":"27023732","id":"PMC_27023732","title":"Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?","date":"2016","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27023732","citation_count":58,"is_preprint":false},{"pmid":"20192949","id":"PMC_20192949","title":"CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis.","date":"2011","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/20192949","citation_count":58,"is_preprint":false},{"pmid":"10462060","id":"PMC_10462060","title":"Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors.","date":"1999","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/10462060","citation_count":58,"is_preprint":false},{"pmid":"9974174","id":"PMC_9974174","title":"The CB1 cannabinoid receptor in the brain.","date":"1998","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/9974174","citation_count":57,"is_preprint":false},{"pmid":"20218784","id":"PMC_20218784","title":"Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.","date":"2010","source":"The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/20218784","citation_count":57,"is_preprint":false},{"pmid":"17669634","id":"PMC_17669634","title":"The CNR1 gene as a pharmacogenetic factor for antipsychotics rather than a susceptibility gene for schizophrenia.","date":"2007","source":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17669634","citation_count":57,"is_preprint":false},{"pmid":"28404744","id":"PMC_28404744","title":"The role of CB1 in intestinal permeability and inflammation.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28404744","citation_count":56,"is_preprint":false},{"pmid":"18833324","id":"PMC_18833324","title":"Loss of cannabinoid receptor CB1 induces preterm birth.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18833324","citation_count":56,"is_preprint":false},{"pmid":"15308578","id":"PMC_15308578","title":"Efficacy in CB1 receptor-mediated signal transduction.","date":"2004","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/15308578","citation_count":55,"is_preprint":false},{"pmid":"22463610","id":"PMC_22463610","title":"CB1 receptor antagonists: new discoveries leading to new perspectives.","date":"2012","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22463610","citation_count":55,"is_preprint":false},{"pmid":"18468662","id":"PMC_18468662","title":"Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder.","date":"2008","source":"Urology","url":"https://pubmed.ncbi.nlm.nih.gov/18468662","citation_count":53,"is_preprint":false},{"pmid":"23916480","id":"PMC_23916480","title":"CB1 cannabinoid receptor-mediated aggressive behavior.","date":"2013","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23916480","citation_count":51,"is_preprint":false},{"pmid":"19659925","id":"PMC_19659925","title":"Association of CNR1 and FAAH endocannabinoid gene polymorphisms with anorexia nervosa and bulimia nervosa: evidence for synergistic effects.","date":"2009","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/19659925","citation_count":51,"is_preprint":false},{"pmid":"9106243","id":"PMC_9106243","title":"Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential.","date":"1997","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/9106243","citation_count":50,"is_preprint":false},{"pmid":"37160876","id":"PMC_37160876","title":"Structural basis for activation of CB1 by an endocannabinoid analog.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37160876","citation_count":48,"is_preprint":false},{"pmid":"15542757","id":"PMC_15542757","title":"Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors.","date":"2004","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/15542757","citation_count":47,"is_preprint":false},{"pmid":"10871313","id":"PMC_10871313","title":"CB1 cannabinoid receptor-mediated cell migration.","date":"2000","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/10871313","citation_count":46,"is_preprint":false},{"pmid":"17881126","id":"PMC_17881126","title":"No association of CNR1 gene variations with susceptibility to schizophrenia.","date":"2007","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17881126","citation_count":43,"is_preprint":false},{"pmid":"17702901","id":"PMC_17702901","title":"Expression of cannabinoid CB1 receptors in models of diabetic neuropathy.","date":"2007","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/17702901","citation_count":41,"is_preprint":false},{"pmid":"19919870","id":"PMC_19919870","title":"Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans.","date":"2009","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/19919870","citation_count":39,"is_preprint":false},{"pmid":"30174119","id":"PMC_30174119","title":"Hippocampal CB1 Receptors Control Incidental Associations.","date":"2018","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/30174119","citation_count":37,"is_preprint":false},{"pmid":"18505678","id":"PMC_18505678","title":"The cannabinoid CB1 receptor is expressed in pancreatic delta-cells.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18505678","citation_count":37,"is_preprint":false},{"pmid":"19075713","id":"PMC_19075713","title":"Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.","date":"2008","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/19075713","citation_count":37,"is_preprint":false},{"pmid":"29058339","id":"PMC_29058339","title":"Linking Mitochondria and Synaptic Transmission: The CB1 Receptor.","date":"2017","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/29058339","citation_count":36,"is_preprint":false},{"pmid":"28752643","id":"PMC_28752643","title":"Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition.","date":"2017","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/28752643","citation_count":36,"is_preprint":false},{"pmid":"32512776","id":"PMC_32512776","title":"Targeting the Endocannabinoid CB1 Receptor to Treat Body Weight Disorders: A Preclinical and Clinical Review of the Therapeutic Potential of Past and Present CB1 Drugs.","date":"2020","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32512776","citation_count":35,"is_preprint":false},{"pmid":"17292652","id":"PMC_17292652","title":"No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents.","date":"2007","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17292652","citation_count":35,"is_preprint":false},{"pmid":"31968549","id":"PMC_31968549","title":"Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.","date":"2020","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/31968549","citation_count":34,"is_preprint":false},{"pmid":"16169563","id":"PMC_16169563","title":"Development and expression of neuropathic pain in CB1 knockout mice.","date":"2005","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16169563","citation_count":34,"is_preprint":false},{"pmid":"25863168","id":"PMC_25863168","title":"CB1 receptors modulate affective behaviour induced by neuropathic pain.","date":"2015","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/25863168","citation_count":34,"is_preprint":false},{"pmid":"25430877","id":"PMC_25430877","title":"Cannabinoid CB1 receptors mediate the effects of dipyrone.","date":"2015","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25430877","citation_count":32,"is_preprint":false},{"pmid":"19165169","id":"PMC_19165169","title":"Variants in the CNR1 and the FAAH genes and adiposity traits in the community.","date":"2009","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19165169","citation_count":31,"is_preprint":false},{"pmid":"33083022","id":"PMC_33083022","title":"Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1-Drp1 pathway.","date":"2020","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/33083022","citation_count":31,"is_preprint":false},{"pmid":"21790903","id":"PMC_21790903","title":"Further evidence for association of polymorphisms in the CNR1 gene with cocaine addiction: confirmation in an independent sample and meta-analysis.","date":"2011","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/21790903","citation_count":30,"is_preprint":false},{"pmid":"35063024","id":"PMC_35063024","title":"The cannabinoid receptor I (CB1) enhanced the osteogenic differentiation of BMSCs by rescue impaired mitochondrial metabolism function under inflammatory condition.","date":"2022","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/35063024","citation_count":30,"is_preprint":false},{"pmid":"24950219","id":"PMC_24950219","title":"Cardiorespiratory anomalies in mice lacking CB1 cannabinoid receptors.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24950219","citation_count":28,"is_preprint":false},{"pmid":"31725603","id":"PMC_31725603","title":"The association of endocannabinoid receptor genes (CNR1 and CNR2) polymorphisms with depression: A meta-analysis.","date":"2019","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31725603","citation_count":27,"is_preprint":false},{"pmid":"40044849","id":"PMC_40044849","title":"A cryptic pocket in CB1 drives peripheral and functional selectivity.","date":"2025","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/40044849","citation_count":26,"is_preprint":false},{"pmid":"26739712","id":"PMC_26739712","title":"Physiological impact of CB1 receptor expression by hippocampal GABAergic interneurons.","date":"2016","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/26739712","citation_count":26,"is_preprint":false},{"pmid":"11341859","id":"PMC_11341859","title":"The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users.","date":"2001","source":"Addiction biology","url":"https://pubmed.ncbi.nlm.nih.gov/11341859","citation_count":26,"is_preprint":false},{"pmid":"22850347","id":"PMC_22850347","title":"MAPK14 and CNR1 gene variant interactions: effects on brain volume deficits in schizophrenia patients with marijuana misuse.","date":"2012","source":"Psychological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22850347","citation_count":26,"is_preprint":false},{"pmid":"23422373","id":"PMC_23422373","title":"CNR1 gene and risk of the metabolic syndrome in patients with schizophrenia.","date":"2013","source":"Journal of clinical psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23422373","citation_count":25,"is_preprint":false},{"pmid":"20370713","id":"PMC_20370713","title":"Understanding functional residues of the cannabinoid CB1.","date":"2010","source":"Current topics in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20370713","citation_count":25,"is_preprint":false},{"pmid":"18563799","id":"PMC_18563799","title":"Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.","date":"2008","source":"Chemical record (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/18563799","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47015,"output_tokens":7322,"usd":0.125438,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16765,"output_tokens":4008,"usd":0.092012,"stage2_stop_reason":"end_turn"},"total_usd":0.21745,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"CB1 receptor is a G protein-coupled receptor coupled to G proteins; it inhibits adenylyl cyclase and regulates ion channels in the CNS, and is activated by cannabinoid ligands including endogenous agonists.\",\n      \"method\": \"Pharmacological characterization, binding studies, effector system assays\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — extensively replicated across multiple labs using in vitro assays, binding studies, and functional effector measurements; foundational receptor pharmacology\",\n      \"pmids\": [\"9336020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CB1 receptor couples to Gi/o proteins to inhibit adenylate cyclase, regulate Ca2+ channels and K+ channels, and stimulate the MAP kinase pathway; the juxtamembrane C-terminal region extending from helix VII is proposed to activate G proteins.\",\n      \"method\": \"Expression in cell lines, electrophysiology, biochemical effector assays\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs with functional effector assays and channel recordings\",\n      \"pmids\": [\"9974174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Protein kinase C (PKC) phosphorylates a single serine (S317) in the third intracellular loop of CB1, and this phosphorylation disrupts CB1-mediated modulation of potassium and calcium channels; mutating S317 to alanine eliminated PKC-mediated disruption without affecting basal channel modulation.\",\n      \"method\": \"Site-directed mutagenesis, PKC phosphorylation of fusion protein, electrophysiology in AtT-20 cells transfected with rat CB1\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation assay plus mutagenesis plus functional electrophysiology, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"9526000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CB1 receptors are rapidly internalized following agonist binding via clathrin-coated pits; internalization does not require activated Gα subunits; a region of the extreme carboxy terminus (last 14 residues) is necessary for internalization. Recycling of sequestered receptor requires endosomal acidification and dephosphorylation.\",\n      \"method\": \"Pharmacological internalization assays with hypertonic sucrose blockade, C-terminal truncation mutants, new protein synthesis inhibition\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-mapping with multiple truncation mutants, pharmacological dissection, and cell biological assays in a single lab\",\n      \"pmids\": [\"10428044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"GRK3 and β-arrestin 2 mediate homologous CB1 receptor desensitization; residues within the C-terminal tail (418–439), specifically phosphorylation sites S426 and S430, are required for GRK3/β-arrestin-dependent desensitization but not for internalization. CB1 desensitization and internalization are thus governed by distinct receptor domains.\",\n      \"method\": \"Xenopus oocyte expression system with GRK3/β-arrestin co-expression, K+ conductance electrophysiology, site-directed mutagenesis (S426A, S430A), AtT-20 cell internalization assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in oocyte system, mutagenesis, and multiple functional readouts in a single rigorous study\",\n      \"pmids\": [\"10234009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CB1 receptor activation mediates cell migration (chemotaxis and chemokinesis) via pertussis toxin-sensitive Gi proteins; this migratory response depends on MAP kinase activation but not on adenylyl cyclase inhibition.\",\n      \"method\": \"Modified Boyden chamber migration assay in HEK293 cells stably expressing human CB1, pertussis toxin treatment, PD098059 (MEK inhibitor) treatment, SR141716A antagonism\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional migration assay with pharmacological dissection, single lab, two orthogonal mechanistic probes\",\n      \"pmids\": [\"10871313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CB1 receptor signal transduction efficacy depends on coupling to Gi/o proteins, with evidence for regional differences in G protein selectivity in brain; CB1 can also interact with Gs or Gq in some cellular contexts.\",\n      \"method\": \"[35S]GTPγS binding assays, adenylyl cyclase assays, brain regional comparisons\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical assays across multiple brain regions, single review consolidating multiple experiments\",\n      \"pmids\": [\"15308578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CB1R signals primarily through Gi/o proteins to inhibit adenylyl cyclase and regulate ion channels; it also activates MAPK pathways (p42/p44, p38, JNK) via Gi/o; activated/phosphorylated CB1R associates with β-arrestins, forming signaling complexes; CB1R can form homo- and heterodimers/oligomers with altered pharmacological properties.\",\n      \"method\": \"Biochemical assays, co-immunoprecipitation, resonance energy transfer approaches, functional signaling assays\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling assays cited from multiple studies, review consolidating replicated findings\",\n      \"pmids\": [\"19620237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CB1 receptor physically interacts with β2-adrenoceptors as demonstrated by BRET; co-expression of β2-adrenoceptors reduces CB1 constitutive activity, increases CB1 cell-surface expression, enhances Gαi-dependent ERK phosphorylation, and decreases non-Gαi-mediated CREB phosphorylation. These interactions were confirmed in primary human trabecular meshwork cells endogenously co-expressing both receptors.\",\n      \"method\": \"Bioluminescence resonance energy transfer (BRET), co-expression in HEK293H cells, ERK and CREB signaling assays, primary human ocular cell experiments\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BRET physical interaction plus functional signaling assays in both heterologous and endogenous cell system\",\n      \"pmids\": [\"20590567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB1 and CB2 receptors form functional heteromers in transfected neuronal cells and in rat brain (pineal gland, nucleus accumbens, globus pallidus); within CB1-CB2 heteromers, co-activation produces negative cross-talk in Akt phosphorylation and neurite outgrowth; CB1 antagonists can block CB2 agonist effects and vice versa (bidirectional cross-antagonism).\",\n      \"method\": \"Biophysical (BRET/FRET) and biochemical (co-immunoprecipitation) approaches in transfected neuronal cells and rat brain tissue; Akt phosphorylation and neurite outgrowth assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP plus biophysical BRET/FRET plus functional cross-antagonism assays, demonstrated in both transfected cells and native brain tissue\",\n      \"pmids\": [\"22532560\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CB1 receptor co-expression with GPR55 leads to heteromer formation; this heteromer inhibits GPR55-mediated NFAT and SRE transcription factor activation and ERK1/2 activation; conversely, GPR55 presence enhances CB1R-mediated ERK1/2 and NFAT activation. Internalization of both receptors is not affected by heteromerization.\",\n      \"method\": \"Co-immunoprecipitation, BRET, transcription factor reporter assays (NFAT, SRE), ERK1/2 phosphorylation assays in HEK293 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — BRET plus co-IP plus functional signaling assays, single lab\",\n      \"pmids\": [\"23161546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CB1 receptor activation by AEA or ACEA (CB1-specific agonist) enhances neuronal differentiation of neural stem cells but not astrocyte or oligodendrocyte differentiation; CB1 activation causes long-term inhibition of ERK1/2 signaling, and pharmacological inhibition of ERK1/2 recapitulates the pro-neuronal differentiation effect.\",\n      \"method\": \"Pharmacological activation/antagonism in mouse NSCs, RT-PCR, Western blot, morphometric analysis, gene array profiling, ERK1/2 pathway inhibition\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CB1-specific agonist/antagonist combined with pathway inhibition and multiple readouts, single lab\",\n      \"pmids\": [\"23372698\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Loss of CB1 function (pharmacological or genetic, Cnr1 knockout) in mice causes defects in axonal growth and fasciculation during embryonic development; CB1 is required for normal axonal pathfinding in vivo.\",\n      \"method\": \"CB1 pharmacological inhibition, morpholino knockdown in zebrafish, loss-of-function phenotype analysis (axon pathfinding/fasciculation)\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological plus genetic (morpholino) knockdown with defined developmental phenotype in two model systems\",\n      \"pmids\": [\"18378465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Genetic inactivation of CB1 (Cnr1 knockout), but not CB2, induces preterm birth in mice; CB1 deficiency alters progesterone/estrogen ratios before parturition; CB1 inactivation causes aberrant CRH and corticosterone secretion, and a CRH antagonist restores normal parturition timing in Cnr1 null mice.\",\n      \"method\": \"Cnr1 and Cnr2 targeted deletion mouse models, pharmacological inactivation, radioimmunoassay for steroid hormones, CRH antagonist rescue\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus pharmacological rescue with endocrine measurements, multiple orthogonal approaches in a single rigorous study\",\n      \"pmids\": [\"18833324\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CB1 receptor mediates cannabinoid-induced suppression of glutamatergic (Schaffer collateral-CA1) synaptic transmission in the hippocampus; CB1 knockout mice of two independent lines show no cannabinoid-mediated suppression at this synapse.\",\n      \"method\": \"Extracellular field recordings in hippocampal slices from two independently generated CB1-/- mouse lines vs. wild-type controls\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across two independent CB1 KO mouse lines with electrophysiological recordings\",\n      \"pmids\": [\"16527424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CB1 receptor signaling promotes angiogenesis; siRNA-mediated knockdown or pharmacological antagonism of CB1 inhibits bFGF-induced endothelial proliferation, migration, and capillary-like tube formation via ERK, Akt, FAK, JNK, Rho, and MMP-2 pathways; CB1 blockade also inhibits neovascular growth in vivo (rabbit cornea assay and mouse retinopathy model).\",\n      \"method\": \"siRNA knockdown, pharmacological antagonism, in vitro endothelial proliferation/migration/tube formation assays, in vivo corneal and retinal neovascularization models\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological loss-of-function with multiple in vitro and in vivo readouts, multiple signaling pathway measurements\",\n      \"pmids\": [\"21460248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of CB1 bound to the negative allosteric modulator (NAM) ORG27569 and agonist CP55940 reveals that ORG27569 binds to an extrahelical site within the inner leaflet of the membrane overlapping with a conserved cholesterol interaction site; the ternary complex captures an intermediate receptor state where aromatic residues at the base of the agonist-binding pocket adopt inactive conformation despite orthosteric pocket contraction.\",\n      \"method\": \"X-ray crystallography of CB1 ternary complex (NAM + agonist)\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure with functional context, single lab but definitive structural method\",\n      \"pmids\": [\"31659318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The positive allosteric modulator (PAM) ZCZ011 binds to an extrahelical site at the TM2-TM3-TM4 surface of CB1; TM2 rearrangement is critical for allosteric signal propagation; ZCZ011 promotes TM2 rearrangement favoring receptor activation, while the NAM ORG27569 (also binding TM2-TM3-TM4) impedes TM2 rearrangement. Both allosteric modulators converge on the same TM2 rearrangement mechanism.\",\n      \"method\": \"X-ray crystallography, cryo-EM structures of CB1 with PAM ZCZ011, unbiased and biased molecular dynamics simulations, site-directed mutagenesis, functional signaling assays\",\n      \"journal\": \"Nature chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure and cryo-EM combined with MD simulations and mutagenesis in a single rigorous multi-method study\",\n      \"pmids\": [\"35637350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structure of CB1 bound to an endocannabinoid analog (AMG315) in an active signaling complex reveals ligand binding pocket details; ligand interactions with TM2 residues drive conformational changes on the intracellular side of TM2 that are unique to CB1 and are a determinant of G protein activation efficacy; the 'toggle switch' residues F200(3.36) and W356(6.48) are functionally important for activation.\",\n      \"method\": \"Cryo-EM structure determination of agonist-CB1-G protein complex, molecular docking, molecular dynamics simulations, mutagenesis, signaling assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure combined with MD simulations, mutagenesis, and functional signaling assays in a single rigorous study\",\n      \"pmids\": [\"37160876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A cryptic pocket in CB1 (identified by molecular dynamics simulations, leading to D2.50) can be targeted by positively charged agonist derivatives to achieve peripheral restriction and dampened arrestin recruitment; the lead ligand VIP36 occupying this cryptic pocket shows 100-fold dose separation between peripheral analgesic efficacy and centrally mediated side effects in mouse pain models, with limited tolerance development.\",\n      \"method\": \"Computational MD simulation-guided design, structure determination, pharmacological assays for G protein vs arrestin signaling bias, in vivo mouse pain models (three models), PK studies\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure determination plus mutagenesis/pharmacology plus in vivo validation with multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"40044849\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CB1 receptors specifically in hippocampal GABAergic neurons are necessary and sufficient for mediated (incidental) learning; deletion and re-expression of CB1R in hippocampal GABAergic neurons abolishes and rescues mediated learning respectively; paired sensory cues induce protein synthesis-dependent upregulation of hippocampal CB1R expression and facilitate long-term plasticity at inhibitory synapses.\",\n      \"method\": \"Cell-type-specific CB1R deletion and re-expression (conditional KO and rescue), sensory preconditioning behavioral paradigm, chemogenetic manipulation of hippocampal GABAergic neurons, electrophysiology for synaptic plasticity\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with cell-type-specific rescue plus chemogenetics plus synaptic plasticity recordings, multiple orthogonal approaches\",\n      \"pmids\": [\"30174119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CB1 receptors in hippocampal GABAergic interneurons inhibit GABA release; deletion of CB1R from GABAergic neurons enhances frequency and kinetics of spontaneous IPSCs in CA1 pyramidal neurons and impairs acquisition of spatial memory and novel object recognition, without affecting tonic inhibition, paired-pulse facilitation, or LTP.\",\n      \"method\": \"Cell-type-specific CB1R knockout in GABAergic neurons, patch clamp and field potential recordings, behavioral cognitive testing\",\n      \"journal\": \"Pflugers Archiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with electrophysiology and behavioral phenotyping, multiple orthogonal readouts\",\n      \"pmids\": [\"26739712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Expression of CB1 mRNA in the striatum of Huntington's disease transgenic mice (R6/1, R6/2) is progressively reduced due to decreased transcription; the CB1 gene has two exons separated by an 18.4 kb intron with a GC-rich promoter; the progressive decline is caused by altered transcription factor activity due to mutant huntingtin expression.\",\n      \"method\": \"RT-PCR, promoter analysis, transcription start site mapping, comparison of HD transgenic vs wild-type mice at multiple ages\",\n      \"journal\": \"European journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene structure characterization plus functional transcription analysis in transgenic disease model, single lab\",\n      \"pmids\": [\"15606779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CB1 receptor forms heteromers with Smoothened (Smo), the Hedgehog pathway transducer, as demonstrated by proximity ligation assay; cannabinoids reduce Shh signaling by inhibiting Smo, and a CB1 receptor antagonist attenuates cannabinoid-induced birth defects; CB1-Smo heteromers suggest allosteric CB1-Smo interaction.\",\n      \"method\": \"Proximity ligation assay (PLA) in mouse/zebrafish embryo models, CB1 antagonist rescue, Shh pathway reporter assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — proximity ligation (single method for interaction) plus pharmacological rescue, single lab\",\n      \"pmids\": [\"31690747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CB1 receptor activation (ACEA) protects against brain ischemia/reperfusion injury by inhibiting mitochondrial fission via Drp1; CB1 agonist ACEA reduced OGD/R-induced neuronal injury and MCAO-induced infarct volume; neuroprotective effects were blocked by CB1 antagonist AM251 or Drp1 upregulation, establishing a CB1-Drp1 pathway.\",\n      \"method\": \"OGD/R model in neuronal cells, MCAO rat model, co-administration of CB1 antagonist AM251 and Drp1 overexpression, mitochondrial fission and apoptosis assays\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological intervention with genetic Drp1 manipulation in both in vitro and in vivo models, single lab\",\n      \"pmids\": [\"33083022\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CB1 receptor activation in human bone marrow MSCs enhances osteogenic differentiation and rescues mitochondrial energy metabolism (OCR and mitochondrial membrane potential) impaired by inflammatory cytokines; CB1 activation promotes JNK and p38 MAPK signaling and inhibits ERK1/2; this effect was linked to enhanced mitochondrial electron transport chain activity.\",\n      \"method\": \"CB1 agonist/antagonist treatment, CB1 knockdown, Seahorse metabolic analysis, JC-10 MMP assay, Western blot for MAPK pathways, osteogenic differentiation assays\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CB1 knockdown plus pharmacological activation with functional metabolic and differentiation readouts, single lab\",\n      \"pmids\": [\"35063024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor is expressed specifically in pancreatic delta-cells (somatostatin-positive) in mouse, rat, and human islets; CB1 is not detected in alpha-, beta-, or PP-cells of islets; monoacylglycerol lipase (MAGL) is expressed in delta-cells and FAAH in alpha-cells.\",\n      \"method\": \"Confocal immunofluorescence microscopy with co-localization for somatostatin, insulin, glucagon markers; RT-PCR in islets and cell lines\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — immunofluorescence co-localization in three species (mouse, rat, human) with cell-type markers, single lab\",\n      \"pmids\": [\"18505678\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CB1 receptors are functionally present within brain mitochondria (mtCB1); acute activation of mtCB1 alters mitochondrial ATP generation, synaptic transmission, and memory performance.\",\n      \"method\": \"Mitochondrial fractionation, functional assays of mitochondrial ATP production, synaptic transmission measurements, memory behavioral tests\",\n      \"journal\": \"BioEssays\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review consolidating subcellular fractionation and functional data from multiple studies\",\n      \"pmids\": [\"29058339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor activation inhibits trigeminovascular neuronal responses to A- and C-fiber inputs from the dura mater; this inhibition is blocked by CB1 antagonist SR141716 but not CB2 antagonist AM630, establishing CB1-mediated inhibition of trigeminocervical complex neurons.\",\n      \"method\": \"Extracellular electrophysiology of TCC neurons in rats, cannabinoid agonist WIN55,212 and anandamide treatment with selective antagonists SR141716 and AM630\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo electrophysiology with selective antagonist dissection, single lab\",\n      \"pmids\": [\"17018694\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CB1 receptor mRNA expression in the Fallopian tube shows temporal (luteal > follicular) variation likely regulated by progesterone; CB1 mRNA is attenuated in Fallopian tube and decidua of women with ectopic pregnancy, suggesting that CB1 signaling regulates embryo transport in the human oviduct.\",\n      \"method\": \"RT-PCR and immunohistochemistry of timed Fallopian tube biopsies from women with and without ectopic pregnancy\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — expression analysis (RT-PCR/IHC) with clinical correlation, no direct functional manipulation\",\n      \"pmids\": [\"19093002\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CNR1 encodes CB1, a class A GPCR that couples primarily to Gi/o proteins to inhibit adenylyl cyclase, suppress voltage-gated Ca2+ channels, activate inwardly rectifying K+ channels, and stimulate MAPK pathways; it undergoes GRK3/β-arrestin-2-mediated homologous desensitization via phosphorylation of S426/S430 on its C-terminal tail, and agonist-driven internalization via clathrin-coated pits dependent on the distal C-terminus; structurally, it possesses an orthosteric ligand-binding pocket and an extrahelical allosteric site at TM2-TM3-TM4 where both positive and negative allosteric modulators act by promoting or impeding TM2 rearrangement; a cryptic pocket near D2.50 can be targeted to achieve peripheral restriction and biased (G protein-favored) signaling; CB1 forms functional heteromers with CB2, GPR55, β2-adrenoceptors, and Smoothened with distinct signaling consequences; it is expressed presynaptically in neurons to mediate retrograde inhibition of neurotransmitter release, in hippocampal GABAergic interneurons to control inhibitory transmission and specific forms of learning, within mitochondria to regulate ATP production, and in peripheral tissues including intestinal epithelium, endothelial cells, and pancreatic delta-cells to modulate permeability, angiogenesis, and islet hormone secretion, respectively.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CNR1 encodes CB1, a class A G protein-coupled receptor that couples predominantly to Gi/o proteins to inhibit adenylyl cyclase, regulate Ca2+ and K+ channels, and stimulate MAPK cascades (p42/p44, p38, JNK), with regional and context-dependent flexibility in G protein selectivity [#0, #1, #6, #7]. Signaling output is shaped by phosphorylation-dependent regulation: PKC phosphorylates S317 in the third intracellular loop to disrupt channel modulation [#2], while GRK3/\\u03b2-arrestin-2 acting on C-terminal sites S426/S430 drive homologous desensitization, a process governed by a receptor domain distinct from the extreme C-terminal region required for clathrin-mediated agonist-induced internalization [#3, #4, #7]. Structural studies define an orthosteric agonist pocket with F200(3.36)/W356(6.48) toggle-switch residues and TM2-dependent intracellular conformational changes that determine G protein activation efficacy, plus an extrahelical TM2-TM3-TM4 allosteric site where positive and negative modulators converge on TM2 rearrangement, and a cryptic pocket near D2.50 exploitable for peripherally restricted, G protein-biased analgesia [#16, #17, #18, #19]. CB1 forms functional heteromers with \\u03b22-adrenoceptors, CB2, GPR55, and Smoothened, each reconfiguring downstream signaling and cross-regulation [#8, #9, #10, #23]. Functionally, CB1 in hippocampal GABAergic interneurons inhibits GABA release to control inhibitory transmission, spatial memory, and mediated learning [#20, #21], mediates retrograde suppression of glutamatergic transmission [#14], and acts during development in axonal pathfinding and parturition timing [#12, #13]. It also operates in non-neuronal contexts including endothelial angiogenesis [#15], mitochondrial ATP regulation and Drp1-dependent fission [#24, #27], and is expressed selectively in pancreatic delta-cells [#26]. Reduced CB1 transcription in striatum accompanies Huntington's disease progression in transgenic mice [#22].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established CB1 as a Gi/o-coupled GPCR whose juxtamembrane C-terminal region engages G proteins to inhibit adenylyl cyclase, regulate ion channels, and activate MAPK, defining the core transduction logic of the receptor.\",\n      \"evidence\": \"Pharmacological characterization, cell line expression, electrophysiology, and biochemical effector assays\",\n      \"pmids\": [\"9336020\", \"9974174\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve atomic basis of G protein selectivity\", \"Context-dependent Gs/Gq coupling not yet defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved that desensitization and internalization of CB1 are governed by distinct receptor domains \\u2014 GRK3/\\u03b2-arrestin-2 acting on C-terminal S426/S430 versus a separate distal C-terminal sequence for clathrin-mediated endocytosis \\u2014 plus PKC-dependent S317 modulation, clarifying how receptor signaling is independently regulated.\",\n      \"evidence\": \"Site-directed mutagenesis, in vitro phosphorylation, oocyte and AtT-20 reconstitution, internalization assays, electrophysiology\",\n      \"pmids\": [\"9526000\", \"10428044\", \"10234009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify phosphatases driving recycling-coupled dephosphorylation\", \"In vivo physiological consequences of each phosphosite not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showed CB1 drives cell migration through Gi-dependent MAPK activation independent of adenylyl cyclase inhibition, demonstrating effector-branch-specific physiological outputs.\",\n      \"evidence\": \"Boyden chamber migration assays in CB1-expressing HEK293 cells with pertussis toxin and MEK inhibitor dissection\",\n      \"pmids\": [\"10871313\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Heterologous overexpression system only\", \"Endogenous migratory contexts not tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetically established CB1 as the obligatory mediator of cannabinoid-induced suppression of glutamatergic transmission in hippocampus, confirming its role in synaptic signaling in native tissue.\",\n      \"evidence\": \"Field recordings in hippocampal slices from two independent CB1 knockout lines\",\n      \"pmids\": [\"16527424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not localize the presynaptic source of receptor\", \"Retrograde messenger identity not addressed here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined developmental, endocrine, and tissue-specific roles of CB1 \\u2014 axonal pathfinding, parturition timing via CRH/steroid regulation, delta-cell-restricted islet expression, and trigeminovascular inhibition \\u2014 broadening the receptor beyond classical neuromodulation.\",\n      \"evidence\": \"Cnr1 knockout/morpholino phenotyping, CRH antagonist rescue with steroid radioimmunoassay, islet immunofluorescence across three species, in vivo TCC electrophysiology\",\n      \"pmids\": [\"18378465\", \"18833324\", \"18505678\", \"17018694\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Delta-cell CB1 signaling output on hormone secretion not functionally tested\", \"Cell-autonomous versus systemic contributions to parturition unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrated that CB1 physically heteromerizes with \\u03b22-adrenoceptors, CB2, and GPR55, reconfiguring constitutive activity, surface expression, and ERK/Akt/NFAT signaling, establishing receptor-receptor crosstalk as a layer of CB1 regulation.\",\n      \"evidence\": \"BRET/FRET, reciprocal co-immunoprecipitation, transcription reporter and phosphorylation assays in heterologous cells, native brain tissue, and primary ocular cells\",\n      \"pmids\": [\"20590567\", \"22532560\", \"23161546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural interface of heteromers undefined\", \"Physiological prevalence of each heteromer in vivo not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed CB1 in hippocampal GABAergic neurons is necessary and sufficient for inhibitory transmission control and specific forms of learning, pinpointing a defined neural circuit substrate for CB1 cognitive function.\",\n      \"evidence\": \"Cell-type-specific conditional knockout and rescue, chemogenetics, sensory preconditioning behavior, IPSC and plasticity recordings\",\n      \"pmids\": [\"30174119\", \"26739712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of activity-dependent CB1 upregulation not defined\", \"Generalizability beyond hippocampal GABAergic neurons untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Crystallography revealed an extrahelical allosteric site overlapping a cholesterol interaction site and captured an intermediate receptor state, providing the structural basis for allosteric modulation of CB1.\",\n      \"evidence\": \"X-ray crystallography of CB1 ternary complex with NAM ORG27569 and agonist CP55940\",\n      \"pmids\": [\"31659318\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single allosteric modulator captured\", \"Did not yet define the mechanistic step linking allosteric site to activation\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established that positive and negative allosteric modulators binding the TM2-TM3-TM4 surface converge on a shared TM2 rearrangement that gates activation, unifying the mechanism of bidirectional allosteric control.\",\n      \"evidence\": \"Crystallography, cryo-EM with PAM ZCZ011, biased/unbiased MD simulations, mutagenesis, signaling assays\",\n      \"pmids\": [\"35637350\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinetics of TM2 transition not quantified\", \"Endogenous regulators of this site unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Active-state cryo-EM defined ligand-driven TM2 conformational changes unique to CB1 and toggle-switch residues F200/W356 as determinants of G protein activation efficacy, linking ligand chemistry to coupling output.\",\n      \"evidence\": \"Cryo-EM of agonist-CB1-G protein complex, docking, MD, mutagenesis, signaling assays\",\n      \"pmids\": [\"37160876\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Arrestin-bound active state not resolved here\", \"Determinants of biased signaling not yet structurally mapped\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified a cryptic D2.50 pocket targetable to achieve peripherally restricted, G protein-biased agonism with separation of analgesia from central side effects, demonstrating actionable structure-guided pharmacology.\",\n      \"evidence\": \"MD-guided design, structure determination, biased signaling pharmacology, three in vivo mouse pain models, PK studies\",\n      \"pmids\": [\"40044849\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term safety and clinical translation untested\", \"Endogenous role of this cryptic pocket unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CB1 subcellular pools \\u2014 plasma membrane, mitochondria, and heteromeric assemblies \\u2014 are coordinated to produce distinct physiological outputs in a given cell remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism targeting CB1 to mitochondria undefined\", \"Quantitative partitioning between signaling pools unknown\", \"Integration of heteromer-specific signaling in native tissue not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 6, 7]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [8, 9, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [24, 27]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 7]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [14, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CB2\", \"GPR55\", \"ADRB2\", \"SMO\", \"ARRB2\", \"GRK3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}